BD has become the subject of a lawsuit from Tela Bio, with the rival maker of surgical mesh implants saying the major medtech wielded its sector dominance to push competing products out of the hernia ...

MALVERN, Pa., June 02, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today ...

This article first appeared on GuruFocus. TELA Bio Inc (NASDAQ:TELA) is set to release its Q3 2025 earnings on Nov 13, 2025. The consensus estimate for Q3 2025 revenue is $21.79 million, and the ...

Becton, Dickinson & Company (NYSE: BDX) is facing allegations that it abused monopoly power in the U.S. hernia mesh market to block competition, raise costs for hospitals, and limit treatment choices ...

MALVERN, PA — TELA Bio, Inc. (NASDAQ: TELA) announced a new round of equity awards designed to attract and retain talent as the commercial-stage medtech firm expands its workforce and advances its ...

(RTTNews) - Tela Bio, Inc. (TELA) on Wednesday priced an underwritten public offering of 12 million shares at $2.25 per share and, pre-funded warrants to purchase 5.800 million shares at $2.2499 per ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.